Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Apr 30;13(4):626-630.
doi: 10.21037/tau-23-589. Epub 2024 Apr 18.

Metabolic enzymes moonlighting to drive enzalutamide resistance in prostate cancer

Maria Rusan #  1   2   3 , Simone Weiss #  1   3 , Karina Dalsgaard Sørensen  1   3
Affiliations
Editorial

Metabolic enzymes moonlighting to drive enzalutamide resistance in prostate cancer

Maria Rusan et al. Transl Androl Urol. .
No abstract available

Keywords: PGAM2; Prostate cancer; clustered regularly interspaced short palindromic repeats screening (CRISPR screening); enzalutamide resistance; metabolic enzymes.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-23-589/coif). M.R. reports advisory board work and consultancy with Pfizer, and paid lecture from Ipsen. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Buttigliero C, Tucci M, Bertaglia V, et al. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat Rev 2015;41:884-92. 10.1016/j.ctrv.2015.08.002 - DOI - PubMed
    1. Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol 2017;71:151-4. 10.1016/j.eururo.2016.07.032 - DOI - PMC - PubMed
    1. Bluemn EG, Coleman IM, Lucas JM, et al. Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. Cancer Cell 2017;32:474-489.e6. 10.1016/j.ccell.2017.09.003 - DOI - PMC - PubMed
    1. Chan JM, Zaidi S, Love JR, et al. Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling. Science 2022;377:1180-91. 10.1126/science.abn0478 - DOI - PMC - PubMed
    1. Palit SAL, van Dorp J, Vis D, et al. A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer. Sci Rep 2021;11:13683. 10.1038/s41598-021-93107-w - DOI - PMC - PubMed